Clinical features of progressive supranuclear palsy.
Richardson’s syndrome
longitudinal MRI
parkinsonism
phenotype
progressive supranuclear palsy
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
05
2023
accepted:
18
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Progressive supranuclear palsy (PSP) is a clinically heterogenous atypical parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is challenging but essential. This study aims to characterize the clinical manifestations, magnetic resonance imaging (MRI), and longitudinal MRI changes of PSP in China. Clinical and MRI presentations were compared among 150 cases with PSP. Then the longitudinal MRI changes among 20 patients with PSP were further explored. Additionally, a series of midbrain-based MRI parameters was compared between PSP-P and PD. Throughout the course of the disease, there were differences in the symptoms of the fall and hand tremor between the PSP-RS and PSP-P. There were significant differences in the six midbrain-based MRI parameters between the PSP-RS and the PSP-P, including hummingbird sign, midbrain diameter, midbrain to pons ratio (MTPR), midbrain area, midbrain area to pons area ratio (Ma/Pa), and midbrain tegmental length (MBTegm). Longitudinal MRI studies revealed that the annual rel.ΔMTPR and rel.Δ (Ma/Pa) for PSP were 5.55 and 6.52%, respectively; additionally, PSP-RS presented a higher decline rate than PSP-P. Moreover, MTPR ≤0.56, midbrain diameter ≤ 0.92, midbrain area ≤ 1.00, and third ventricle width ≤ 0.75 could identify PSP-P from PD. PSP-P differs from PSP-RS regarding clinical manifestations, MRI, and longitudinal MRI changes. MRI parameters could be potential imaging markers to identify PSP-P from PD.
Sections du résumé
Background
UNASSIGNED
Progressive supranuclear palsy (PSP) is a clinically heterogenous atypical parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is challenging but essential. This study aims to characterize the clinical manifestations, magnetic resonance imaging (MRI), and longitudinal MRI changes of PSP in China.
Method
UNASSIGNED
Clinical and MRI presentations were compared among 150 cases with PSP. Then the longitudinal MRI changes among 20 patients with PSP were further explored. Additionally, a series of midbrain-based MRI parameters was compared between PSP-P and PD.
Results
UNASSIGNED
Throughout the course of the disease, there were differences in the symptoms of the fall and hand tremor between the PSP-RS and PSP-P. There were significant differences in the six midbrain-based MRI parameters between the PSP-RS and the PSP-P, including hummingbird sign, midbrain diameter, midbrain to pons ratio (MTPR), midbrain area, midbrain area to pons area ratio (Ma/Pa), and midbrain tegmental length (MBTegm). Longitudinal MRI studies revealed that the annual rel.ΔMTPR and rel.Δ (Ma/Pa) for PSP were 5.55 and 6.52%, respectively; additionally, PSP-RS presented a higher decline rate than PSP-P. Moreover, MTPR ≤0.56, midbrain diameter ≤ 0.92, midbrain area ≤ 1.00, and third ventricle width ≤ 0.75 could identify PSP-P from PD.
Conclusion
UNASSIGNED
PSP-P differs from PSP-RS regarding clinical manifestations, MRI, and longitudinal MRI changes. MRI parameters could be potential imaging markers to identify PSP-P from PD.
Identifiants
pubmed: 37711994
doi: 10.3389/fnagi.2023.1229491
pmc: PMC10498458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1229491Informations de copyright
Copyright © 2023 Wen, Yang, Jiao, Zhang, Lin, Zhu, Xu, Zhou, Weng, Liao, Zhou, Wang, Guo, Yan, Jiang, Tang and Shen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurology. 2013 May 14;80(20):1856-61
pubmed: 23616165
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
Mov Disord. 2019 Apr;34(4):487-495
pubmed: 30759325
Diagnostics (Basel). 2022 Oct 07;12(10):
pubmed: 36292111
Mov Disord. 2019 Sep;34(9):1307-1314
pubmed: 31299107
Parkinsonism Relat Disord. 2020 Mar;72:1-6
pubmed: 32036297
Curr Opin Neurol. 2022 Apr 1;35(2):230-239
pubmed: 35191407
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
J Neurol. 2023 May;270(5):2451-2467
pubmed: 36633672
Mov Disord. 2022 Jun;37(6):1272-1281
pubmed: 35403258
Neurology. 2005 Jun 28;64(12):2050-5
pubmed: 15985570
Mov Disord. 2006 Aug;21(8):1182-8
pubmed: 16673397
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
J Neurol. 2014 Aug;261(8):1575-83
pubmed: 24888315
Parkinsonism Relat Disord. 2012 Mar;18(3):252-6
pubmed: 22079523
Brain Pathol. 2007 Jan;17(1):74-82
pubmed: 17493041
Neurol Res. 2019 Feb;41(2):110-117
pubmed: 30373485
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Mov Disord. 2016 Jan;9(1):3-13
pubmed: 26828211
Brain. 2008 May;131(Pt 5):1362-72
pubmed: 18385183
Neurology. 2016 Sep 20;87(12):1266-73
pubmed: 27558375
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Mov Disord. 2017 Jul;32(7):995-1005
pubmed: 28500752
Front Neurol. 2020 Nov 12;11:603161
pubmed: 33281738
Mov Disord. 2019 Aug;34(8):1144-1153
pubmed: 30726566
Mov Disord. 2011 Feb 15;26(3):527-33
pubmed: 21287599
Neurodegener Dis. 2017;17(1):31-37
pubmed: 27614955
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
J Neurol. 2021 Apr;268(4):1526-1532
pubmed: 33277666
Acta Neurol Belg. 2022 Apr;122(2):357-362
pubmed: 33595832
Diagnostics (Basel). 2022 Dec 02;12(12):
pubmed: 36553028
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Neurology. 2016 Nov 8;87(19):2016-2025
pubmed: 27742814
J Neurol. 2016 Dec;263(12):2419-2423
pubmed: 27624121
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):441-5
pubmed: 20360166
Curr Neurol Neurosci Rep. 2018 Feb 17;18(3):12
pubmed: 29455271
J Neurol Neurosurg Psychiatry. 2017 May;88(5):402-411
pubmed: 28250027
J Clin Med. 2022 May 10;11(10):
pubmed: 35628828
Brain. 2007 Jun;130(Pt 6):1566-76
pubmed: 17525140
BMC Neurol. 2020 Mar 30;20(1):114
pubmed: 32228519
Mol Psychiatry. 2019 Aug;24(8):1112-1134
pubmed: 30635637
JAMA Neurol. 2020 Mar 1;77(3):377-387
pubmed: 31860007
Mov Disord. 2019 Aug;34(8):1228-1232
pubmed: 30884545
Front Neurol. 2020 Mar 10;11:180
pubmed: 32218768
Mov Disord. 2019 Sep;34(9):1284-1293
pubmed: 31283855
J Neurol Sci. 2003 Jun 15;210(1-2):57-60
pubmed: 12736089